Clinical Trials Logo

Clinical Trial Summary

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05182840
Study type Interventional
Source Boehringer Ingelheim
Contact Boehringer Ingelheim
Phone 1-800-243-0127
Email [email protected]
Status Recruiting
Phase Phase 2
Start date January 11, 2022
Completion date July 4, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03907657 - Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02238067 - Survey on Anemia Therapy in Patients With Chronic Kidney Disease Not on Dialysis N/A
Completed NCT01194154 - A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA) Phase 2
Completed NCT02263833 - An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice N/A
Recruiting NCT04078750 - PLATO - Medication Adherence in Transplant Recipients N/A
Active, not recruiting NCT03189212 - Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation N/A
Enrolling by invitation NCT05064267 - Hemostatic Profiles in Pediatric CKD
Not yet recruiting NCT03590067 - Oral Findings in a Group of Egyptian Pediatric Patients at Endstage Renal Disease
Recruiting NCT04014127 - Coronary Microvascular Dysfunction in Chronic Kidney Disease
Recruiting NCT04626323 - Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease Phase 2
Recruiting NCT03615235 - APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
Recruiting NCT04515797 - QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir Phase 4
Active, not recruiting NCT03850756 - Early Diagnosis of Kidney Damage Associated With Tobacco Use
Completed NCT00125593 - Study of Heart and Renal Protection Phase 4
Completed NCT03307707 - New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder N/A
Recruiting NCT05119816 - Music Therapy Intervention During Kidney Biopsy. N/A
Recruiting NCT03816111 - Targeted Education ApproaCH to Improve Peritoneal Dialysis Outcomes Trial N/A
Completed NCT01318512 - An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis N/A
Recruiting NCT04029402 - Molecular Analysis of Diabetic Kidney Disease Biopsies